Actively Recruiting
Increased Inflammation-resolving Activity by Omega-3 Monoglycerides in Peripheral Blood Mononuclear Cells (PBMC).
Led by SCF Pharma · Updated on 2026-04-17
200
Participants Needed
1
Research Sites
407 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this biological study is to provide Dr. Samuel Fortin's laboratory with a continuous supply of blood mononuclear cells (PBMCs) so that he can pursue research on the potential beneficial effects of monoglyceride omega-3 fatty acids on the resolution of inflammation.
CONDITIONS
Official Title
Increased Inflammation-resolving Activity by Omega-3 Monoglycerides in Peripheral Blood Mononuclear Cells (PBMC).
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participant aged of at least 18 years old.
You will not qualify if you...
- Use of omega-3 supplements within 7 days of study start.
- Use of anti-inflammatory medications such as Aspirin, Ibuprofen (Motrin, Advil), Celecoxib (Celebrex), diclofenac (Cambia, Cataflam, Voltaren) within 7 days of study start.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
SCF Pharma
Rimouski, Quebec, Canada, G0K 1P0
Actively Recruiting
Research Team
S
Samuel Fortin, PhD
CONTACT
A
Anne-Julie Landry, M.Sc
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here